Stratifin as a Novel Diagnostic Biomarker in Serum for Diffuse Alveolar DamageNoriaki Arakawa(National Institute of Health Sciences), Masayuki Hanaoka(Shinshu University)Research SquareJuly 14, 202110.21203/rs.3.rs-690487/v1Cited by 1SaveCiteExport RISWatch citationsRelated PapersClinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma|PLoS ONE|2016|38Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage|Nature Communications|2022|29